AIMS: To test the hypothesis that @entity5735 inhibition in C-peptide negative Type 1 @entity6 would reduce @entity413 variability and exposure to hypoglycaemia and therefore may indirectly enhance counter-regulatory responses to subsequent hypoglycaemia. METHODS: We conducted a 12-week double-blind, randomized, placebo-controlled crossover study. The study was conducted in a tertiary hospital outpatient clinic, with additional studies performed in a clinical research centre. After obtaining informed consent, we recruited 14 subjects with moderately well controlled Type 1 @entity6 (HbA1c 64    2 mmol/mol) of long duration (20.5    2.7 years). The subjects received 12 weeks' therapy with oral @entity15072 (5 mg) or placebo. @entity413 variability, assessed via continuous @entity413 monitoring, together with frequency of hypoglycaemia, hypoglycaemia awareness and symptomatic, cognitive and counter-regulatory hormone responses to experimental hypoglycaemia, were assessed. Additional outcome measures included @entity4051 c level, weight, total daily insulin dose and adverse events. RESULTS: @entity15072 co-therapy did not reduce @entity413 variability (low blood @entity413 index, average daily risk range), hypoglycaemia frequency or awareness and did not improve counter-regulatory hormonal responses during experimental hypoglycaemia (area under the curve for @entity1425 25 775 vs 24 454, for placebo vs @entity15072 , respectively; P=0.76). CONCLUSIONS: No additional benefit of @entity5735 inhibition co-therapy with @entity15072 in the management of Type 1 @entity6 was observed. This article is protected by copyright. All rights reserved.

@entity15072 co-therapy in C-peptide-negative Type 1 XXXX does not improve counter-regulatory responses to hypoglycaemia.

@entity4051 :: ('3039', 'Gene') :: ['HbA1'] @entity5735 :: ('1803', 'Gene') :: ['dipeptidyl peptidase-4'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity1425 :: ('MESH:D004837', 'Chemical') :: ['adrenaline'] @entity15072 :: ('MESH:C502994', 'Chemical') :: ['saxagliptin', 'Saxagliptin'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose', 'Glucose']
@entity6 :: (MESH:D003920,Disease) :: ['diabetes']
